Argos Therapeutics Inc (ARGS) 8.35 $ARGS
Argos Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:30PM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th, 2015, at 3:30 p.m. Eastern Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the pivotal ADAPT phase 3 trial, as well as the AGS-004 program. The conference will be held at the Waldorf Astoria in New York, NY.
ARGS: 8.35 (-0.12)
Argos Therapeutics Chief Operating Officer to Speak at Phacilitate Cell & Gene Therapy Forum 2015
GlobeNewswire - Fri Jan 23, 10:00AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced that Dr. Fred Miesowicz, the company's chief operating officer and vice president of manufacturing, will speak at the Phacilitate Cell & Gene Therapy Forum 2015 to be held January 26-28 at the Grand Hyatt in Washington, D.C. Dr. Miesowicz is scheduled to present a case study during a focus session titled, "Logistics 1: Placing logistics at the heart of the cell and gene therapy business model," beginning at 2:30pm ET on January 26. He will also participate in a breakfast briefing titled, "Creating a cell therapy manufacturing system for commercial production," at 7:45am ET on January 27.
ARGS: 8.35 (-0.12)
Argos Therapeutics Director of Immunology to Speak at the GTCbio Novel Immunotherapeutics Summit 2015
GlobeNewswire - Thu Jan 22, 9:02AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos" , a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced the company's director of immunology, Dr. Mark DeBenedette, has been selected as a distinguished speaker for the GTCbio Novel Immunotherapeutics Summit 2015 to be held January 29-30 in San Diego, Calif. Dr. DeBenedette is scheduled to speak during the 7 Immunotherapeutics and Immunomonitoring conference on January 29 at 4:05pm PST at the Paradise Point Resort & Spa in a session moderated by Dr. Christopher Heery, National Cancer Institute.
ARGS: 8.35 (-0.12)
Argos Therapeutics Chief Scientific Officer to Speak at the Personalized Medicine World Conference 2015
GlobeNewswire - Tue Jan 20, 7:30AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos" , a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced that Dr. Charles Nicolette, the company's chief scientific officer and vice president of research and development, will speak at the Personalized Medicine World Conference (PMWC) 2015 to be held January 26-28 at the Computer History Museum in Mountain View, Calif. Dr. Nicolette is scheduled to speak during a session titled "Immunotherapy: New Options for Cancer Treatment," beginning at 9:15am PST on January 27.
ARGS: 8.35 (-0.12)
Argos Therapeutics (ARGS) Jumps: Stock Rises 18.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 8:25AM CST
Argos Therapeutics (ARGS) was a big mover last session, with shares rising over 18% on the day.
ARGS: 8.35 (-0.12), AFFX: 11.45 (+0.02)
Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 3:20PM CST
Argos Therapeutics Inc.'s (ARGS) AGS-004 failed to meet the primary endpoint in a phase IIb study for the treatment of patients suffering from chronic HIV-1 infection.
ARGS: 8.35 (-0.12), PFE: 34.64 (-0.23), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
Argos HIV immunotherapy candidate fails in clinical trial
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:13AM CST
ARGS: 8.35 (-0.12)
Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV
GlobeNewswire - Fri Jan 09, 6:00AM CST
Findings from Phase 2b trial support clinical development of AGS-004 in adult eradication and pediatric studies.
ARGS: 8.35 (-0.12)
Argos Therapeutics to Present at Biotech Showcase 2015
GlobeNewswire - Tue Jan 06, 3:30PM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will present the Biotech Showcase(TM) 2015 Conference on Monday, January 12, 2015 at 2:30 p.m. Pacific Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the ADAPT trial, as well as the AGS-004 program. The conference will be held at the Parc 55 Wyndham Hotel in San Francisco, CA.
ARGS: 8.35 (-0.12)
Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies
GlobeNewswire - Tue Jan 06, 7:31AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos" , a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced a collaboration with Saint-Gobain's Performance Plastics division, a leader in high-performance components and solutions using engineered polymers. Under the terms of the agreement, Saint-Gobain will partner with Argos to design, integrate and scale production of a range of disposables for use in the automated manufacturing of Argos' lead product candidate, AGS-003, currently being tested in a Phase III clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).
ARGS: 8.35 (-0.12)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), IMMU: 3.84 (unch), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ARGS: 8.35 (-0.12), NVO: 43.76 (+0.61), IDRA: 4.10 (-0.14), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), CBMG: 24.32 (-1.17), CELGZ: 3.17 (-0.04)
Argos Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 8:37AM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will participate in a fireside chat at the 26Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. Eastern Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the ADAPT trial, as well as the AGS-004 program. The conference will be held at The New York Palace Hotel, in New York, NY.
ARGS: 8.35 (-0.12)
Argos Therapeutics Receives 2014 Red Herring North America Top 100 Award
GlobeNewswire - Mon Nov 24, 7:30AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos" , a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced the company has been honored with a 2014 Red Herring North America Top 100 award.
ARGS: 8.35 (-0.12)
Argos Therapeutics (ARGS) Jumps: Stock Gains 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:46AM CST
Argos Therapeutics (ARGS) was a big mover last session, with shares rising over 7% on the day.
BIIB: 391.66 (-0.45), ARGS: 8.35 (-0.12), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Argos Therapeutics' (ARGS) CEO Jeff Abbey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 8:45PM CST
ARGS: 8.35 (-0.12)
Argos Therapeutics misses by $0.22, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:28PM CST
ARGS: 8.35 (-0.12)
Argos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights
GlobeNewswire - Thu Nov 13, 3:09PM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today reported financial results for the third quarter ended September 30, 2014, and provided an update on the Company's clinical programs.
ARGS: 8.35 (-0.12)
Philippe Van Holle Joins Argos Therapeutics Board of Directors
GlobeNewswire - Thu Nov 13, 7:30AM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos" , a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(R) technology platform, today announced the appointment of Philippe Van Holle to the company's board of directors.
ARGS: 8.35 (-0.12)
Argos Therapeutics to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:30AM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 3:00 p.m. Eastern Time. Mr. Abbey will provide an update of the AGS-003 clinical development program, including the ADAPT trial, as well as the AGS-004 program. The conference will be held at The New York Palace Hotel, in New York, NY.
ARGS: 8.35 (-0.12)
Argos Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:30PM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th, 2015, at 3:30 p.m. Eastern Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the pivotal ADAPT phase 3 trial, as well as the AGS-004 program. The conference will be held at the Waldorf Astoria in New York, NY.
ARGS: 8.35 (-0.12)
Argos Therapeutics Chief Operating Officer to Speak at Phacilitate Cell & Gene Therapy Forum 2015
GlobeNewswire - Fri Jan 23, 10:00AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced that Dr. Fred Miesowicz, the company's chief operating officer and vice president of manufacturing, will speak at the Phacilitate Cell & Gene Therapy Forum 2015 to be held January 26-28 at the Grand Hyatt in Washington, D.C. Dr. Miesowicz is scheduled to present a case study during a focus session titled, "Logistics 1: Placing logistics at the heart of the cell and gene therapy business model," beginning at 2:30pm ET on January 26. He will also participate in a breakfast briefing titled, "Creating a cell therapy manufacturing system for commercial production," at 7:45am ET on January 27. ARGS: 8.35 (-0.12)
Argos Therapeutics Director of Immunology to Speak at the GTCbio Novel Immunotherapeutics Summit 2015
GlobeNewswire - Thu Jan 22, 9:02AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced the company's director of immunology, Dr. Mark DeBenedette, has been selected as a distinguished speaker for the GTCbio Novel Immunotherapeutics Summit 2015 to be held January 29-30 in San Diego, Calif. Dr. DeBenedette is scheduled to speak during the 7 Immunotherapeutics and Immunomonitoring conference on January 29 at 4:05pm PST at the Paradise Point Resort & Spa in a session moderated by Dr. Christopher Heery, National Cancer Institute. ARGS: 8.35 (-0.12)
Argos Therapeutics Chief Scientific Officer to Speak at the Personalized Medicine World Conference 2015
GlobeNewswire - Tue Jan 20, 7:30AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced that Dr. Charles Nicolette, the company's chief scientific officer and vice president of research and development, will speak at the Personalized Medicine World Conference (PMWC) 2015 to be held January 26-28 at the Computer History Museum in Mountain View, Calif. Dr. Nicolette is scheduled to speak during a session titled "Immunotherapy: New Options for Cancer Treatment," beginning at 9:15am PST on January 27. ARGS: 8.35 (-0.12)
Argos Therapeutics (ARGS) Jumps: Stock Rises 18.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 8:25AM CST
Argos Therapeutics (ARGS) was a big mover last session, with shares rising over 18% on the day.
ARGS: 8.35 (-0.12), AFFX: 11.45 (+0.02)
Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 3:20PM CST
Argos Therapeutics Inc.'s (ARGS) AGS-004 failed to meet the primary endpoint in a phase IIb study for the treatment of patients suffering from chronic HIV-1 infection.
ARGS: 8.35 (-0.12), PFE: 34.64 (-0.23), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
Argos HIV immunotherapy candidate fails in clinical trial
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:13AM CST
ARGS: 8.35 (-0.12)
Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV
GlobeNewswire - Fri Jan 09, 6:00AM CST
Findings from Phase 2b trial support clinical development of AGS-004 in adult eradication and pediatric studies.
ARGS: 8.35 (-0.12)
Argos Therapeutics to Present at Biotech Showcase 2015
GlobeNewswire - Tue Jan 06, 3:30PM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will present the Biotech Showcase(TM) 2015 Conference on Monday, January 12, 2015 at 2:30 p.m. Pacific Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the ADAPT trial, as well as the AGS-004 program. The conference will be held at the Parc 55 Wyndham Hotel in San Francisco, CA.
ARGS: 8.35 (-0.12)
Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies
GlobeNewswire - Tue Jan 06, 7:31AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced a collaboration with Saint-Gobain's Performance Plastics division, a leader in high-performance components and solutions using engineered polymers. Under the terms of the agreement, Saint-Gobain will partner with Argos to design, integrate and scale production of a range of disposables for use in the automated manufacturing of Argos' lead product candidate, AGS-003, currently being tested in a Phase III clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). ARGS: 8.35 (-0.12)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), IMMU: 3.84 (unch), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ARGS: 8.35 (-0.12), NVO: 43.76 (+0.61), IDRA: 4.10 (-0.14), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), CBMG: 24.32 (-1.17), CELGZ: 3.17 (-0.04)
Argos Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 8:37AM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will participate in a fireside chat at the 26Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. Eastern Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the ADAPT trial, as well as the AGS-004 program. The conference will be held at The New York Palace Hotel, in New York, NY.
ARGS: 8.35 (-0.12)
Argos Therapeutics Receives 2014 Red Herring North America Top 100 Award
GlobeNewswire - Mon Nov 24, 7:30AM CST
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis(R) technology platform, today announced the company has been honored with a 2014 Red Herring North America Top 100 award. ARGS: 8.35 (-0.12)
Argos Therapeutics (ARGS) Jumps: Stock Gains 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:46AM CST
Argos Therapeutics (ARGS) was a big mover last session, with shares rising over 7% on the day.
BIIB: 391.66 (-0.45), ARGS: 8.35 (-0.12), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Argos Therapeutics' (ARGS) CEO Jeff Abbey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 8:45PM CST
ARGS: 8.35 (-0.12)
Argos Therapeutics misses by $0.22, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:28PM CST
ARGS: 8.35 (-0.12)
Argos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights
GlobeNewswire - Thu Nov 13, 3:09PM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today reported financial results for the third quarter ended September 30, 2014, and provided an update on the Company's clinical programs.
ARGS: 8.35 (-0.12)
Philippe Van Holle Joins Argos Therapeutics Board of Directors
GlobeNewswire - Thu Nov 13, 7:30AM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"
, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(R) technology platform, today announced the appointment of Philippe Van Holle to the company's board of directors. ARGS: 8.35 (-0.12)
Argos Therapeutics to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:30AM CST
Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 3:00 p.m. Eastern Time. Mr. Abbey will provide an update of the AGS-003 clinical development program, including the ADAPT trial, as well as the AGS-004 program. The conference will be held at The New York Palace Hotel, in New York, NY.
ARGS: 8.35 (-0.12)
